This #InternationalChildhoodCancerDay we're celebrating findings from @CancerGrand Challenges team NexTGen 🙌
They've made an exciting discovery about our immune system, which could lead to more advanced #Immunotherapies and cancer vaccines 💉
Click below to read more 👇
RoslinCT is excited to be manufacturing exa-cel, the world’s first CRISPR gene-edited cell-based therapy for a genetic disease, for the treatment of sickle cell disease and transfusion-dependent thalassemia patients in the UK as part of the manufacturing network for @VertexPharma
Proud to be involved with this, in our @RoyalFreeNHS facility for the GMP part, translating such inspiring research.
Now for the important task of showing it works in the clinic
Interesting collab between @BlueRockTx & UK based @bitbio for Tregs from ips cells.
Not long after the AZ/Quell collaboration seems like lots of interest in Tregs.
Is there clinical data compelling yet? https://t.co/vfTKXqMEd7
@JimWatsonPF@RoyalFreeNHS@uclcancer Yes and no.
For instance, most biologics will have been manufactured and ready for distribution but won't be on-site until ordered and patient ready for administration. Availability for use is the key... and consistency.
Autolus have improve consistent in this regard
Interesting talk from Dr Juliana Dias from the CCGTT @RoyalFreeNHS . Manufacturing over clinical 100 batches of allo and autologous CAR-Ts for early phase clinical trials mostly from @uclcancer led research, some collaborating with Autolus.
Vein to QP certification <20days
@JimWatsonPF@RoyalFreeNHS@uclcancer Within a month most likely. From previous Autolus data they defined vein to delivery time as it is what is controllable from the company / manufacturing side so it is ready at clinical site.
That last bit for patient administration is often variable/uncontrollable due to patient
Interesting talk from Dr Juliana Dias from the CCGTT @RoyalFreeNHS . Manufacturing over clinical 100 batches of allo and autologous CAR-Ts for early phase clinical trials mostly from @uclcancer led research, some collaborating with Autolus.
Vein to QP certification <20days
Interim results from pan-ErbB targeted CAR-T for HNSCC.
Cells injected intratumour so lymphodepletion not required.
Safety: CRS grade 2 or lower
Efficacy: low patient # but disease stabilisation and CR w/ pembro & onc virus.
@KingsCollegeLon@Leucidbio
https://t.co/a9bjRYzaAK
Unlicensed stem cell alert @MHRAgovuk
I thought this was more prevalent in the US than UK, but this group offer nothing related to Trials or state their licence.
Not to mention their sketchy explanations for the evidence and science
https://t.co/yNfYeh7Dii